Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Funds / Redmile Biopharma Investments II, L.P.

Redmile Biopharma Investments II, L.P.

MatureClosed to new capitalFundADV: Venture Capital FundRedmile GroupDelaware
Amounts, each with its basis
Vintage
2019basis: form d first sale
Target
unknownnot announced
First close
unknownnever inferred from a Form D
Final close
unknownonly from an announcement or an LP disclosure
Announced size
unknown
Form D offering
$675Mwhat may be sold, not what was raised; file 021-335974, sworn by the adviser or filed under this vehicle
Form D sold
$675Mas of the filing of Mar 5, 2020, 137 investors
First sale
Mar 22, 2019
Reported GAV
$828Mon the Form ADV filed Jul 3, 2024; the fund's assets, never its size or dry powder
Owners (ADV)
138
Reported on ADV
Mar 29, 2019 to Jul 3, 2024
Fundraising evidence
Closed to new capital
Form D filed or amended 2020-03-05: the stated $675.4M offering reported fully sold (fr-1)
evidence dated Mar 5, 2020. A Form D offering is permission to sell, not a fund in market; an amount sold is never a close; an evergreen offering amended every year is not a raise.
Lifecycle
Mature
vintage 4 to 7 years
age years: 7first sale: 2019-03-22vintage year: $2,019adv gav as of: 2024-07-03vintage basis: form_d_first_saleform d sold usd: $675Mform d offering usd: $675Mform d latest filed at: 2020-03-05
The fund's own reporting through time
14 Form ADV filings
FiledTypeGross asset value OwnersMin. investmentAdviser-ownedAudit
Mar 29, 2019Venture Capital Fund$0
27$5.0M1%yes
Mar 30, 2020Venture Capital Fund$674M
102$5.0M8%yes
Aug 27, 2020Venture Capital Fund$674M
102$5.0M8%yes
Feb 26, 2021Venture Capital Fund$674M
102$5.0M8%yes
Mar 31, 2021Venture Capital Fund$1.4B
138$5.0M7%yes
Dec 2, 2021Venture Capital Fund$1.4B
138$5.0M7%yes
Feb 9, 2022Venture Capital Fund$1.4B
138$5.0M7%yes
Mar 31, 2022Venture Capital Fund$1.1B
138$5.0M7%yes
May 6, 2022Venture Capital Fund$1.1B
138$5.0M7%yes
Aug 15, 2022Venture Capital Fund$1.1B
138$5.0M7%yes
Mar 31, 2023Venture Capital Fund$779M
138$5.0M7%yes
May 5, 2023Venture Capital Fund$779M
138$5.0M7%yes
Mar 28, 2024Venture Capital Fund$828M
138$5.0M7%yes
Jul 3, 2024Venture Capital Fund$828M
138$5.0M7%yes
Principals and agents
5 principals on Form D, 2 placement agents
  • Mike Lee Executive Officer
  • Amrit Nagpal Executive Officer
  • Redmile Group, LLC Executive Officer
  • Jeremy Green Executive Officer
  • Redmile Biopharma Investments II (GP), LLC Promoter
  • Hollister Associates, LLC placement agent
  • J.P. Morgan Securities LLC placement agent
Limited partners and their reported performance
0 public LP reports
No public LP has reported this vehicle. The LP tape is read from public pension disclosures (see Limited partners); a fund appears here only when an LP’s report names it.
Investments attributed to this vehicle
0
No investment attributed to this vehicle. The firm’s investments sit on the firm; a fund gets one only when a source names the vehicle.
Timeline
3 events
  1. Mar 5, 2020
    Redmile Biopharma Investments II, L.P. filed Form D/A: $675,420,000 sold of $675,420,000, Venture Capital Fund
    Form D filed Fact SEC EDGAR Form D data sets (quarterly)
  2. Mar 29, 2019
    Redmile Biopharma Investments II, L.P. filed Form D: $331,350,000 sold of $600,000,000, Venture Capital Fund
    Form D filed Fact SEC EDGAR Form D data sets (quarterly)
  3. Mar 29, 2019
    Redmile Biopharma Investments II, L.P. first reported on Form ADV by Redmile Group (Venture Capital Fund)
    Fund first reported on Form ADV Fact SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Evidence
52 observations
Every observation on this vehicle